Your Messages Inbox
Your Article Summary
See Latest ArticlesCertolizumab pegol (Cimzia): Anti-TNF-alpha mAb approved for the treatment of rheumatoid arthritis
Formulary , 06/10/09
Tumor necrosis factor (TNF)-alpha is a proinflammatory cytokine that plays a key role in inflammatory processes. Certolizumab is a humanized monoclonal antibody (mAb) that neutralizes TNF-alpha. This agent was approved on May 2009, for the treatment of adults with moderately to severely active rheumatoid arthritis.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Article Search
Sponsor